General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-06-03 | 2024-03 | 0 | N/A | N/A | N/A |
2023-02-28 | 2022-12 | -0.19 | N/A | N/A | N/A |
2022-11-08 | 2022-09 | -0.25 | -0.2 | 0.05 | 20.00% |
2022-08-15 | 2022-06 | -0.23 | -0.31 | -0.08 | -34.78% |
2022-05-05 | 2022-03 | 0 | N/A | N/A | N/A |
2022-04-01 | 2021-12 | -0.3 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-11-02 | Cantor Fitzgerald | Upgrade | Overweight | |
2022-03-25 | HC Wainwright & Co. | Upgrade | Buy | |
2021-08-09 | HC Wainwright & Co. | Upgrade | Buy | |
2021-01-21 | Alliance Global Partners | Upgrade | Buy | |
2020-07-31 | HC Wainwright & Co. | Upgrade | Buy | |
2020-05-26 | Dawson James | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2018-09-12 | ABG MANAGEMENT, LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2021-03-15 | ASGHAR NAJJAM | Chief Financial Officer | 56.97K | Stock Award(Grant) |
2018-01-23 | ASIA PACIFIC MEDTECH BVI, LTD. | Beneficial Owner of more than 10% of a Class of Security | 8.62M | Sale |
2020-12-15 | FOLLOWWILL DORMAN | Director | 2.13K | Sale |
2021-12-26 | JANDA KIM D | Director | 3.00K | Sale |
2022-12-20 | JI HENRY H | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | State Street Corporation | 50.64M | 15.56M | 10.73% |
2022-12-30 | Blackrock Inc. | 39.42M | 12.11M | 8.35% |
2022-12-30 | Vanguard Group, Inc. (The) | 29.54M | 9.08M | 6.26% |
2022-12-30 | Geode Capital Management, LLC | 8.91M | 2.74M | 1.89% |
2022-12-30 | B. Riley Financial, Inc. | 5.22M | 1.60M | 1.11% |
2022-12-30 | B. Riley Securities, Inc. | 5.22M | 1.60M | 1.11% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-12-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 40.89M | 12.56M | 8.66% |
2022-09-29 | Vanguard Total Stock Market Index Fund | 12.84M | 3.95M | 2.72% |
2022-12-30 | iShares Russell 2000 ETF | 10.36M | 3.18M | 2.20% |
2022-09-29 | Vanguard Extended Market Index Fund | 5.51M | 1.69M | 1.17% |
2022-12-30 | Direxion Shares ETF Tr-Direxion Daily S&P Biotech Bull 3x Sh | 4.27M | 1.31M | 0.91% |
2022-12-30 | iShares Russell 2000 Value ETF | 4.11M | 1.26M | 0.87% |
Split | Date |
---|---|
0.04 : 1 | 2013-08-01 |
0.1 : 1 | 2008-10-07 |
So they said they found covid-19 cure
Wow. Congrats on the bulls that held this.
I never bought in. I would have sold here if I did have it tho. With more hurdles and unknowns ahead take your profits. Just my opinion.
$SRNE Sorrento Therapeutics (SRNE) Announces STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies
Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration.
As recently announced, Sorrento aims to generate an antibody cocktail product that would act as a "protective shield" against SARS-CoV-2 coronavirus infection and remain effective even if virus mutations render a single antibody therapy less effective over time.
Sorrento has been diligently screening billions of antibodies in its proprietary G-MAB fully human antibody library and has so far identified hundreds of antibody candidates that bind the S1 subunit of the SARS-CoV-2 Spike protein. Approximately one dozen of these antibodies have demonstrated the ability to block the S1 protein's interaction with human angiotensin-converting enzyme 2 (ACE2), the receptor used for viral entrance into human cells. These blocking antibodies were further tested for their ability to inhibit SARS-CoV-2 virus infection in an in vitro SARS-CoV-2 virus infection model pursuant to a preclinical testing agreement for COVID-19 therapeutic candidates that was previously announced on March 31, 2020 (Sorrento Therapeutics).
Snake oil, if not confirmed by the scientific community. Only buy when comes from a credible source and FOX news is not credible.
Will this be a good stock to hold over the weekend? $SRNE
$SRNE I told you Monday and Tuesday. This will be up by Friday
Like I said $SRNE will be at $5 by the end of the week. Mark my words fellas.
$SRNE All good NEWS let this stock rise again to greatness
$SRNE Will be at $5 by Friday
$SRNE We need to break the .51 mark to go up. Lets go!
$SRNE Push! Push!!!!!! Let’s go baby you can do this !
$SRNE Can not expect less from you smh